Table 1.
Baseline characteristics of the participants.
| SLE | RA | HD | SLE vs RAP | SLE vs HDP | |
|---|---|---|---|---|---|
| Number of subjects | 53 | 42 | 30 | ||
| Median age (IQR), year | 36.0 (28.0, 46.0) | 63.5 (57.8, 69.3) | 33.5 (27.8, 40.3) | <.001† * | .29† |
| Number of woman (%) | 49 (92.5) | 28 (66.7) | 24 (80) | .003†† * | .16†† |
| Median disease duration (IQR), year | 8.0 (3.0, 17.0) | 7.0 (2.0, 12.8) | NA | .45† | - |
| Median prednisolone dosage (IQR), mg/day | 10.0 (5.0, 15.0) | 0 (0, 2.3) | NA | <.001† * | - |
| Median SLEDAI-2K (IQR) | 4.0 (2.0, 8.0) | NA | NA | - | - |
| Median ESR (IQR), mm/h | 7.0 (4.0, 14.0) | 8.0 (4.0, 19.0) | NA | .65† | - |
ESR = erythrocyte sedimentation rate, HD = healthy donor, IQR = interquartile range, NA = not applicable, RA = rheumatoid arthritis, SLE = systemic lupus erythematosus, SLEDAI-2K = systemic lupus erythematosus disease activity index 2000.
†
Mann–Whitney U test.
††
Fisher exact test.
*
indicates P < .05.